Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles
Michael Galagudza1, Dmitry Korolev1, Viktor Postnov2, Elena Naumisheva2, Yulia Grigorova3, Ivan Uskov1, Eugene Shlyakhto1
1Institute of Experimental Medicine, VA Almazov Federal Heart, Blood and Endocrinology Center, 2Chemical Faculty, St Petersburg State University, 3Department of Pathophysiology, IP Pavlov State Medical University, St Petersburg, Russian Federation
Abstract: Pharmacological agents suggested for infarct size limitation have serious side effects when used at cardioprotective doses which hinders their translation into clinical practice. The solution to the problem might be direct delivery of cardioprotective drugs into ischemic-reperfused myocardium. In this study, we explored the potential of silica nanoparticles for passive delivery of adenosine, a prototype cardioprotective agent, into ischemic-reperfused heart tissue. In addition, the biodegradation of silica nanoparticles was studied both in vitro and in vivo. Immobilization of adenosine on the surface of silica nanoparticles resulted in enhancement of adenosine-mediated infarct size limitation in the rat model. Furthermore, the hypotensive effect of adenosine was attenuated after its adsorption on silica nanoparticles. We conclude that silica nanoparticles are biocompatible materials that might potentially be used as carriers for heart-targeted drug delivery.
Keywords: silica nanoparticles, targeted drug delivery, myocardium, ischemia, reperfusion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]